Login
$MDT
$102.88 +$0.00 (0.0%) After hours

$MDT 8-K SEC Filings

Filed On Filing
19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more

GALWAY, Ireland, October 15, 2026 – Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).

17 Sep 2026 8-K: Other Events

On September 14, 2026, Medtronic plc, a public limited company organized under the laws of Ireland (“Medtronic”), commenced an offer to exchange (the “Exchange Offer”) up to 225,361,295 newly issued shares of common stock, par value $0.0...

01 Sep 2026 8-K: Results of Operations and Financial Condition

Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

03 Jun 2026 8-K: Results of Operations and Financial Condition

Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years

18 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

27 Apr 2026 8-K: Regulation FD Disclosure

Medtronic has determined that an unauthorized party accessed data in certain Medtronic corporate IT systems.

24 Mar 2026 8-K: Regulation FD Disclosure

On March 18, 2026, MiniMed Group, Inc. (MiniMed), a consolidated subsidiary of Medtronic plc (Company) announced that the U.S. Food and Drug Administration (FDA) has cleared the MiniMed Flex™, a next-generation discreet, smartphone-contr...

17 Feb 2026 8-K: Results of Operations and Financial Condition

fiscal 2026 results with highest enterprise revenue growth in 10 quarters

18 Nov 2025 8-K: Results of Operations and Financial Condition

fiscal 2026 financial results, enterprise growth drivers accelerate momentum

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

21 Oct 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

1.The name of the Company is: Medtronic public limited company.

29 Sep 2025 8-K: Entry into a Material Definitive Agreement; Other Events

SIXTH SUPPLEMENTAL INDENTURE, dated as of September 29, 2025 (the “Sixth Supplemental Indenture”), to the Indenture dated as of December 10, 2014 (the “Base Indenture”), between Medtronic, Inc., a Minnesota corporation (the “Company”), a...

16 Sep 2025 8-K: Regulation FD Disclosure; Other Events

Medtronic, Inc., a Minnesota corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule I hereto (the “Underwriters”), for whom Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC are a...

19 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

GALWAY, Ireland – August 19, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025.

23 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation

GALWAY, Ireland – June 23, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent dire...

21 May 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results;

17 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

18 Feb 2025 8-K: Results of Operations and Financial Condition

Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

21 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Medtronic appoints Thierry Piéton as Chief Financial Officer

19 Nov 2024 8-K: Results of Operations and Financial Condition

Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support